Skip to main content
NIH funding notice RFA-AA-24-001

High-Throughput Screening (HTS) Platform for Discovery of Medications to Treat Alcohol Use Disorder (R43/R44 Clinical Trials Not Allowed)

Closed on April 9, 2024.

Posted
December 21, 2023
Close date
April 9, 2024
Activity codes
Not stated on the notice page
Institutes taking part
Not stated on the notice page

The notices it replaced

Its page was not saved, so the notices it replaced are not known.

Who won it before

Competing awards, new and renewals, since FY2014, under this notice and the notices it replaced.

Past awards
1
1 new
First-year cost
$499,987
Institutions
1
1 contact PI

Awards by fiscal year

Fiscal years 2014 to 2026.

Most frequent institutions

  1. CFD RESEARCH CORPORATION1

Most frequent study sections

  1. Special Emphasis Panel (ZAA1 GG (44))1
1 award under RFA-AA-24-001 and the notices it replaced
FYProjectPIsInstitutionFirst-year costStudy section
FY2025A high throughput alcohol screening platform (HT-ASP) incorporating cortical organoids.1R43AA032150-01Roehm, KevinCFD RESEARCH CORPORATION, ALFirst-year cost $499,987Study section ZAA1
Newest fiscal year first, then first-year cost.

Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-13-0.3.2. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.

ScienceDex for departments

Open NIH notices that fit your faculty

See which open NIH funding notices fit each faculty member's CV, why each fits, and who won before.

RFA-AA-24-001: High-Throughput Screening (HTS) Platform for Discovery of Medications to Treat Alcohol Use Disorder (R43/R44 Clinical Trials Not Allowed) | ScienceDex | ConductScience